At the end of last year, a deadly outbreak in a remote part of the Democratic Republic of Congo sparked global panic when it was dubbed ¡°Disease X.¡± The real culprit wasn¡¯t a new mystery illness, but a severe form of a known killer: Malaria complicated by respiratory infections, malnutrition and a lack of access to primary health care services.
The headlines have since moved on, but malaria remains a relentless threat, killing nearly 600,000 people in 2023 ¡ª most of them children under 5. That is more than 1,000 young lives lost every day to a disease we know how to treat.
That means that lifesaving medicines still aren¡¯t reaching those in need. To change that, considerations around access must be baked in from the beginning, starting with the R & D phase and through each stage of a medical products¡¯ lifecycle.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.